InMode Ltd. (INMD): Financial results for Q2 2026
InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno
How this was made
The 30-second read
Why it matters
The earnings release shows flat revenue, margin compression, and modest guidance, likely prompting a sell‑off.
Market read
Primary earnings disclosure for a small‑cap biotech/med‑tech stock; relevant for traders tracking earnings momentum.
What to watch
Record consumables revenue in Asia and ongoing share repurchase may provide longer‑term support.
Background
InMode Ltd., a Nasdaq‑listed medical‑technology company, filed a Form 6‑K reporting its Q2 2026 results and FY guidance.
Ticker impact
Q2 2026 GAAP revenue of $95.6M and FY 2026 guidance of $365‑$375M were disclosed for the first time.
Potential short‑term downside as investors digest weaker margins and modest guidance.
Revenue unchanged YoY and operating margin fell from 24% to 13% (GAAP) signal slower growth; guidance remains below prior expectations.
Market effects
Medical‑device sector may see broader scrutiny of margin pressures.
Limited to U.S. and Israeli markets where InMode operates.
Minimal global impact; primarily affects InMode shareholders.
Counterpoint
Despite margin decline, cash position of $501M could fund strategic acquisitions and support upside.
Key entities
- CompanyInMode Ltd.
Nasdaq‑listed medical‑technology firm.
- ExecutiveMoshik Itzkovich
Chief Financial Officer who commented on results.
